Dihexa research: studies, doses and safety
An experimental memory compound with disputed animal research and no established human dose.
Also called: PNB-0408, N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide.
Nootropic peptides · Modified angiotensin IV peptide; proposed HGF/MET modulator · Evidence: Animal studies only.
No human study giving dihexa directly was identified. Five animal and lab papers include one retracted paper; related fosgonimeton trials cannot establish dihexa's benefit or safety.
Key studies
- Original rat development study: Early animal findings carry a formal notice of concern. (source)
- HGF/MET mechanism paper, retracted: Retracted findings cannot establish the mechanism or a dose. (source)
- Alzheimer-like mouse study: A mouse study reported benefit, with an unresolved route error. (source)
- Negative Huntington-like rat study: No benefit was found in this Huntington-like rat model. (source)
- Working memory after repeated brain injury: A later rat experiment supports some MET-related effects. (source)
Related to Dihexa
- Semax: A Russian nasal peptide with limited human evidence for brain and nerve effects.
- Selank: A Russian nasal anxiety peptide with uncertain long-term benefit and safety.
- PE-22-28: An experimental mood peptide studied in mice, with no human trials found.
- P21: An experimental memory peptide with animal research and no established human dose or safety profile.
- Cerebrolysin: An injectable pig brain mixture with mixed stroke, brain-injury and dementia evidence.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- TGA strengthens compliance focus on unapproved peptide products as part of evolving risk response, Therapeutic Goods Administration · TGA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- <797> FAQs, United States Pharmacopeia · 2023
- Anaphylaxis, NHS · NHS · 2023
- Drug Product Database: Access the database, Health Canada · Health Canada
- Drugs@FDA Data Files, FDA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.